Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2021-07-07 Regulatory Filings
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) by Aptabio regarding the acquisition of a patent for a new crystalline solid form of a chemical compound. It details the patent name, content, holder, and utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2021-07-07 Korean
기타경영사항(특허권취득)(자율공시)(혈액암 치료제)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a blood cancer treatment by Aptabio. It details the patent name, content, patent holder, and utilization plan. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2021-06-24 Korean
기타경영사항(특허권취득)(자율공시)(안질환 예방 또는 치료용 점안 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for an ophthalmic composition. It details the patent name, content, patent holder, and utilization plan. Since it does not fit into specific categories like financial reports, M&A, or director dealings, and is a standard regulatory disclosure of corporate events, it falls under the general regulatory filing category.
2021-06-14 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Aptabio Therapeutics Inc. for the period ending March 31, 2021. It contains detailed financial information, business operations, capital structure, and management discussions, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, but the full report itself. Q1 2021
2021-05-14 Korean
기타경영사항(특허권취득)(자율공시)(혈액암 치료제)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a blood cancer treatment by Aptabio. It details the patent name, content, patent holder, and utilization plan. Since it is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fit into financial reporting, M&A, or other specific categories, it falls under the general regulatory filing category.
2021-04-06 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'Aptabio'. It details the approval of financial statements, dividend resolutions, election of directors and auditors, and other agenda items voted upon during the meeting held on 2021-03-30. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) as it reports the outcome of shareholder votes.
2021-03-30 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.